NHS approves teplizumab, a drug that can delay type 1 diabetes onset by up to three years
England and Wales have approved teplizumab for use on the NHS, making it available through the national health system to certain people at high risk of developing type 1 diabetes. The drug delays the onset of the disease by up to three years. It applies to a subset of at-risk individuals, not people already living with diabetes, and real-world rollout details and patient numbers have not yet been confirmed.
Why it matters
Type 1 diabetes currently has no cure and requires lifelong management, so a treatment that can meaningfully postpone its onset gives at-risk patients more time before facing that burden.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news